Effects of Propolis intake on nutritional status, some inflammatory and anti-inflammatory factors and quality of life in patients with Breast Cancer undergoing chemotherapy.

Effects of Propolis intake on nutritional status, matrix metalloproteinase enzymes, inflammatory, anti-inflammatory and oxidative factors and quality of life in patients with Breast Cancer undergoing chemotherapy.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016062828679N1

Enrollment

Registered

2016-09-08

Start date

2016-09-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer. Malignant neoplasm: Breast, unspecified

Interventions

Intervention 1: A week before the start of chemotherapy in intervention group, 250 mg propolis extract divided in two 125 mg capsules will administered twice daily with breakfast and lunch until the e

Treatment - Drugs

Placebo

A week before the start of chemotherapy in intervention group, 250 mg propolis extract divided in two 125 mg capsules will administered twice daily with breakfast and lunch until the end of treatment

A week before the start of chemotherapy in the placebo group, starch capsules with dose of 250 mg (125 mg twice daily) will administered with breakfast and lunch until the end of treatment (3 months)

Eligibility

Sex/Gender

Female

Age

30 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Stage II and III Breast cancer under chemotherapy; age range 30 to 50 years. Exclusion criteria: heart disease co morbidity; history of hypersensitivity reactions to bee products.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Interlukin b1, 2, 10. Timepoint: Baseline and after intervention. Method of measurement: Elisa, ng/ml.;TNF-a. Timepoint: Baseline and after intervention. Method of measurement: Elisa, ng/ml.;MMP-2, 9. Timepoint: Baseline and after intervention. Method of measurement: Elisa, ng/ml.;Anti oxidant Ezymes. Timepoint: Baseline and after intervention. Method of measurement: Elisa, nmol/l.;Nutritional Status. Timepoint: Baseline and after intervention. Method of measurement: PGSGA questionner.;Mir 21. Timepoint: Baseline and after intervention. Method of measurement: Fold.;Mir638. Timepoint: Baseline and after intervention. Method of measurement: Fold.;Quality of life. Timepoint: Baseline and after intervention. Method of measurement: EORTC QLQ30.	—

Measure

Time frame

Interlukin b1, 2, 10. Timepoint: Baseline and after intervention. Method of measurement: Elisa, ng/ml.;TNF-a. Timepoint: Baseline and after intervention. Method of measurement: Elisa, ng/ml.;MMP-2, 9. Timepoint: Baseline and after intervention. Method of measurement: Elisa, ng/ml.;Anti oxidant Ezymes. Timepoint: Baseline and after intervention. Method of measurement: Elisa, nmol/l.;Nutritional Status. Timepoint: Baseline and after intervention. Method of measurement: PGSGA questionner.;Mir 21. Timepoint: Baseline and after intervention. Method of measurement: Fold.;Mir638. Timepoint: Baseline and after intervention. Method of measurement: Fold.;Quality of life. Timepoint: Baseline and after intervention. Method of measurement: EORTC QLQ30.

—

Secondary

Measure	Time frame
Chemotrapy Complication. Timepoint: Baseline and after intervention. Method of measurement: questionner.;Liver Enzymes. Timepoint: Baseline and after intervention. Method of measurement: Eliza, IU/L.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNazila Darvishi

Shahid Beheshti University of Medical Sciences

naziladarvishy@yahoo.com+98 87 3366 9313

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 14, 2026